{
    "doi": "https://doi.org/10.1182/blood-2021-146777",
    "article_title": "Single Cell Analyses Reveal a Non-Canonical EZH2 Activity As a Main Driver of Retinoic Acid Resistance in PLZF/Rara Leukemia ",
    "article_date": "November 5, 2021",
    "session_type": "602.Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic",
    "abstract_text": "Resistance to treatment is due to the heterogeneity of the tumor which contains a subset of cancer cells that escape treatment and are responsible for the relapse. Acute Promyelocytic Leukemia (APL), the M3 subtype of AML, is a good model to illustrate these problematics. Indeed, APL driven by oncogenic fusion proteins such PML/RARA t(15;17) or PLZF/RARA t(11;17) behave differently to differentiation therapeutics. Both APLs differentiate in vivo upon Retinoic Acid (RA) treatment; however, while PML/RARA APL patients exhibit partial or complete remission, PLZF/RARA APL patients remain clinically resistant. In the present study we aim to decipher the transcriptional and epigenetic networks that is linked to t(11;17) APL resistance towards RA. We took advantage of the PLZF/RARA RA resistant murine APL model to catch relapse-initiating cell features and their vulnerabilities. By developing an integrative single-cell multi-omics analysis (scRNA-seq and scATAC-seq), we uncovered transcriptional and chromatin heterogeneity of the PLZF/RARA APL blasts. We highlighted a subset of cells insensitive to RA-induced differentiation with a strong DNA repair signature (\"Rep\" cluster) and exhibiting a fine tuned transcriptional network targeting the histone methyltransferase Ezh2. To validate the function of Ezh2 in APL physiology, we combined epigenomic studies with RA-treated and non-RA-treated bone marrow transplantation experiments. We revealed high Ezh2 activity that marks the relapse of RA-treated APL. However, targeting Ezh2 methyltransferase activity was not sufficient to achieve disease cure and, suggests an independent methyltransferase Ezh2 activity linked to RA resistance. These findings demonstrate the power of single-cell multi-omics integration to highlight path to sensitize therapy-resistant leukemia cells. In addition, our study uncovers a dual role of Ezh2 in APL and suggests that targeting non-canonical Ezh2 activity could be a new promising therapeutic approach for RA resistant APL. Disclosures Iwama:  Nissan Chemical Corporation: Research Funding.",
    "author_names": [
        "Mathilde Poplineau",
        "Nadine Platet",
        "Adrien Mazuel",
        "L\u00e9onard H\u00e9rault",
        "Shuhei Koide",
        "Wakako Kuribayashi",
        "Nadine Carbuccia",
        "Lia N'Guyen",
        "Julien Vernerey",
        "Motohiko Oshima",
        "Daniel Birnbaum",
        "Christophe Lachaud",
        "Atsushi Iwama",
        "Estelle Duprez"
    ],
    "author_dict_list": [
        {
            "author_name": "Mathilde Poplineau",
            "author_affiliations": [
                "Institut Paoli-Calmettes, CRCM, Marseille, France",
                "Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan",
                "CRCM, Marseille, France"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Nadine Platet",
            "author_affiliations": [
                "Centre de Recherche en Canc\u00e9rologie de Marseille, Marseille, France"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Adrien Mazuel",
            "author_affiliations": [
                "Centre de Recherche en Canc\u00e9rologie de Marseille, Marseille, France"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "L\u00e9onard H\u00e9rault",
            "author_affiliations": [
                "Centre de Recherche en Canc\u00e9rologie de Marseille, Marseille, France"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Shuhei Koide",
            "author_affiliations": [
                "Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Wakako Kuribayashi",
            "author_affiliations": [
                "Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nadine Carbuccia",
            "author_affiliations": [
                "CRCM, CNRS, Inserm, Institut Paoli-Calmettes, MARSEILLE, France"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lia N'Guyen",
            "author_affiliations": [
                "Centre de Recherche en Canc\u00e9rologie de Marseille, Marseille, France"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Julien Vernerey",
            "author_affiliations": [
                "Centre de Recherche en Canc\u00e9rologie de Marseille, Marseille, France"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Motohiko Oshima",
            "author_affiliations": [
                "Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Daniel Birnbaum",
            "author_affiliations": [
                "CRCM, CNRS, Inserm, Institut Paoli-Calmettes, MARSEILLE, France"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Christophe Lachaud",
            "author_affiliations": [
                "Centre de Recherche en Canc\u00e9rologie de Marseille, Marseille, FRA"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Atsushi Iwama",
            "author_affiliations": [
                "Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan",
                "Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Estelle Duprez",
            "author_affiliations": [
                "Centre de Recherche en Canc\u00e9rologie de Marseille, Marseille, France"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-21T21:28:58",
    "is_scraped": "1"
}